Suggested Supplements Apigenin – Page 4

Apigenin is a multi-target dietary flavonoid with preclinical support as a candidate therapy for Down syndrome (DS/trisomy 21), acting on CBS overexpression plus several other Hsa21-linked and secondary pathways that drive oxidative stress, neuroinflammation, impaired neurogenesis, and mitochondrial dysfunction. sciencedirect.com

DS arises from gene-dosage effects of an extra chromosome 21. Overexpressed genes include CBS, DYRK1A, APP, and ETS2. These contribute to intellectual disability, early-onset Alzheimer pathology, metabolic/mitochondrial defects, and altered brain development that is already detectable prenatally. Apigenin (4′,5,7-trihydroxyflavone), abundant in parsley, celery, chamomile, and citrus, was identified computationally (Connectivity Map) as a compound that reverses DS transcriptome signatures across human and mouse tissues. Subsequent work demonstrated safety and partial functional rescue in human T21 amniocytes and the Ts1Cje mouse model. nichd.nih.gov

CBS overexpression, H₂S, and mitochondrial/metabolic effects

CBS (cystathionine β-synthase) lies on 21q22.3 and is overexpressed in DS tissues (typically 1.5- to 3-fold, with regional and cell-type variation; highest in astrocytes in brain). CBS catalyzes the first step of the transsulfuration pathway and is a major source of the gasotransmitter hydrogen sulfide (H₂S). Excess CBS-derived H₂S reversibly inhibits mitochondrial Complex IV, suppressing oxidative phosphorylation, ATP production, and oxygen consumption while shifting metabolism toward glycolysis (“pseudohypoxia”). This contributes to oxidative stress, reduced cell proliferation, and bioenergetic failure in neurons that rely heavily on oxidative phosphorylation. pnas.org

CBS overexpression also depletes homocysteine, methionine, and S-adenosylmethionine while elevating cystathionine, perturbing one-carbon metabolism and DNA methylation. Isolated CBS overexpression is sufficient to produce object-recognition and learning deficits in mice; genetic or pharmacologic correction of CBS dosage/activity improves mitochondrial function, ATP generation, synaptic markers, EEG patterns, and cognition in cellular and rodent DS models. sciencedirect.com

Apigenin is documented as a natural-product CBS inhibitor (IC₅₀ ~83 µM in enzyme assays). Molecular docking and dynamics simulations show stable binding to CBS (scores around −7.8 kcal/mol), comparable to or better than some reference compounds. Patents describe apigenin analogs developed specifically as CBS inhibitors. In DS research communities this property has been used at modest doses to counteract CBS-driven H₂S overproduction and downstream mitochondrial and methylation effects. Combined with apigenin’s antioxidant activity, CBS modulation offers a mechanistic rationale for restoring energy metabolism and reducing oxidative damage. mdpi.com

Additional Hsa21 gene targets (DYRK1A, APP, ETS2)

Network-pharmacology and docking studies identify apigenin as a potential multi-ligand for other DS-relevant proteins:

•  DYRK1A (dual-specificity tyrosine-phosphorylation-regulated kinase 1A): overexpressed kinase that impairs neurogenesis, synaptic function, and heart development. Apigenin docks with high affinity (−9.2 kcal/mol). DYRK1A and CBS show genetic interaction; combined inhibition is theoretically synergistic.

•  APP (amyloid precursor protein): extra copy drives early amyloid-β accumulation and Alzheimer pathology. Apigenin shows strong predicted binding (−8.8 kcal/mol) and has reduced amyloid deposits and improved memory in APP/PS1 mice.

•  ETS2: transcription factor linked to apoptosis and developmental phenotypes; modest docking affinity. pmc.ncbi.nlm.nih.gov

These in-silico interactions require experimental confirmation of functional inhibition at physiologically relevant concentrations, but they support a multi-hit rationale beyond CBS alone.

Transcriptomic, inflammatory, and neurogenic effects (Guedj/Bianchi 2020 and related work)

Apigenin was selected because it produced consistently negative Connectivity Map scores (i.e., opposite to the DS expression signature) across human amniocytes, iPSC-derived neurons, and multiple mouse models. In T21 amniocytes (2 µM), it reduced reactive oxygen species and improved antioxidant capacity without major toxicity at therapeutic concentrations. sciencedirect.com

In Ts1Cje mice, prenatal-plus-lifelong dietary apigenin (high-dose chow, ~333–400 mg/kg/day in the original study) was well tolerated (no increase in birth defects or pup loss). It improved several neonatal developmental milestones and spatial/olfactory memory. Adult effects were sex-specific, with greater rescue of exploratory behavior and long-term hippocampal memory in males. nichd.nih.gov

Mechanistic read-outs (gene expression, protein, and cytokine arrays) showed pleiotropic actions:

•  Reduced oxidative stress and restored redox balance.

•  Inhibition of NF-κB signaling with downstream drops in pro-inflammatory cytokines (IFNG, IL-1A, IL-12p70) and rises in anti-inflammatory mediators (IL-10, IL-12p40). Interferon and JAK-STAT pathways, chronically over-activated in DS, were attenuated.

•  Upregulation of pro-proliferative and neurogenic genes (Ki67, Nestin, Sox2, Pax6) and G2/M cell-cycle regulators (Polo-like kinase pathway).

•  Increased VEGFA (angiogenesis) and IL-7 (neurotrophic support).

•  Partial normalization of several trisomic-region genes and shared upstream regulators (HGF/MET, PTGER2, FOXO/FOXM1 family). pubmed.ncbi.nlm.nih.gov

Collectively these changes are proposed to shift microglia toward a less neurotoxic phenotype, reduce reactive astrogliosis, promote neural-progenitor proliferation, and support vascular and synaptic development.

Translational considerations

Apigenin crosses the placenta and blood–brain barrier, making prenatal or early postnatal use theoretically feasible. It is generally regarded as safe at dietary or modest supplemental doses; high doses can inhibit CYP3A4 and certain drug transporters, so pharmacokinetic interactions require attention. Human clinical data specific to DS remain limited; most evidence is preclinical or from computational/network studies. Sex differences observed in mice, modest CBS potency, and the need for combination approaches (e.g., with more potent DYRK1A inhibitors) are important caveats.

In summary, the rationale rests on (1) documented CBS inhibition that addresses H₂S-mediated mitochondrial and methylation defects, (2) predicted or observed engagement of DYRK1A, APP, and ETS2, and (3) robust, multi-pathway rescue of oxidative stress, neuroinflammation, and neurogenesis in human cells and a well-characterized mouse model. These properties make apigenin a scientifically grounded, low-toxicity candidate for further translational work in DS, particularly as part of a multi-target strategy begun as early as possible.